Updated Asper Dysmorphology menu

We have launched an updated Asper Dysmorphology menu. New phenotypically relevant disease-causing genes have been added to many of the panels including brain malformation, microcephaly, skeletal dysplasia, craniosynostosis and several other panels. Visit www.asperbio.com/asper-dysmorphology to see the whole list of tests.

Updates in Asper Neurogenetics testing menu

We now offer a new test for Congenital Muscular Dystrophy, which covers 29 genes and disease-associated non-coding variants. Cornelia de Lange Syndrome and Limb-Girdle Muscular Dystrophy panels also include the analysis of non-coding variants. In addition, we have added genes to the Limb-Girdle Muscular Dystrophy gene set. Learn more at www.asperbio.com/asper-neurogenetics/

Hereditary ataxia

We have expanded our testing options for different types of hereditary ataxia. NGS panel now covers 148 genes and selected non-coding variants associated with spinocerebellar ataxia, episodic ataxia, and cerebellar ataxia. Repeat expansion analysis is available for 14 genes. CNVs are detected based on sequencing data or by Chromosomal Microarray Analysis. Mitochondrial genome sequencing can also be performed to determine the specific genetic cause of hereditary ataxia. Read more at https://www.asperbio.com/asper-neurogenetics/hereditary-ataxia/


EU60187 Project

Asper Biogene is working on the new project – „Prototype development of pharmacogenetic test“.

Project goals: 

1. To develop a prototype of pharmacogenetic test to maximize drug efficacy and reduce adverse drug reactions for most common drugs (at least 30 drugs) listed in the internationally agreed pharmacogenetic clinical practice guidelines.

2. To develop medical informatics tools for the automatic generation and sharing of web-based pharmacogenetic test reports with doctors and patients through Health and Welfare Information Systems Centre (HWISC) database.

Project period: 06.07.2020 – 06.01.2021

Project has been supported by Enterprise Estonia (EAS) from The European Regional Development Fund. Financial support is up to 24 500,00 Euros.

Asper Reprogenetics News

Female infertility and male factor infertility panels have undergone an extensive upgrade. The panels now consist of 128 and 138 genes respectively. Female infertility panel also contains testing of CGG trinucleotide repeat in the FMR1 gene. Please see www.asperbio.com/asper-reprogenetics/ for more information.

Updated NGS panels

Several NGS panels have been updated, including panels for Brain Malformations, Spinocerebellar Ataxias, and Sensorineural Hearing Loss. Find more about updates at www.asperbio.com/NGS-panels

Important announcement

In critical situation, due to COVID-19 faced by many countries we would like to ensure that we continue providing you with genetic testing services. Our key goal is to continuously offer diagnostic solutions that support healthcare professionals with valuable information and thus contribute to improving patient care. We are committed to maintain the highest level of quality standards in all operations.

In our everyday practice, we follow the WHO guidelines and protective measures of national health authorities to establish safety and health of our employees and customers.

Our laboratory team, clinical and scientific teams are operational and available as usual. As well as customer service will continue to offer assistance. If any new information under these changing circumstances become available we will notify you as soon as possible.

Be safe and healthy! If we can be any of assistance, please do not hesitate to contact us.

Male Factor Infertility test

Male Factor Infertility test has been upgraded from targeted mutation analysis to NGS panel with 60 genes associated with spermatogenic failure and meiotic arrest. Testing for Klinefelter syndrome and AZF deletions is also available. Visit www.asperbio.com/male-factor-infertility to see the full list of genes.

Asper Nephrology

We have launched Asper Nephrology testing portfolio to expand our testing menu and cover more clinical areas. The new portfolio includes tests for common monogenic diseases, as well as complex disorders. To establish the genetic cause of renal diseases we use next-generation sequencing technology to accommodate a broad differential diagnosis. CNV analysis based on sequencing data is also available to enhance precise diagnosis. Visit https://www.asperbio.com/asper-nephrology/ to see the full list of tests.

CNV analysis

We have integrated copy number variation (CNV) detection tool into our everyday workflow. CNV analysis is now available as a new testing option for all NGS panels and whole exome sequencing. 

View the complete list of all tests www.asperbio.com/genetic-tests/

Asper Cardiogenetics updates

We now offer an NGS panel for Hereditary Hemorrhagic Telangiectasia. Additionally, Noonan Syndrome test has been upgraded to Noonan Spectrum Disorders/Rasopathies test including several new disease-causing genes. All NGS panels in Asper Cardiogenetics testing menu are covered by CNV analysis based on sequencing data. Visit https://www.asperbio.com/asper-cardiogenetics/ to learn more.

Updated Asper Oncogenetics menu

We have updated our Asper Oncogenetics menu. Genetic testing for Prostate Cancer is now available. The testing includes sequencing of the panel of genes and CNV analysis. Other NGS panels in the Asper Oncogenetics menu now also include CNV analysis. View our updated pricelist at www.asperbio.com/Asper Oncogenetics

News in Asper Ophthalmics

We are pleased to announce that our NGS panels now include CNV analysis.

In addition, three new genes have been added to the Bardet-Biedl Syndrome panel.

Visit www.asperbio.com/asper-ophthalmics to learn more about our new testing options and see the updated price list.